Eli Lilly Stock News

International Companies Drive Diabesity Innovation

Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.

Eli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024. Its diabetes treatments look particularly encouraging, with Mounjaro's 11

Eva Ados, ERShares chief investment strategist, joins 'Power Lunch' to discuss plays for three stocks, including Meta Platforms, Disney, and Eli Lilly.

The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i

Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.

Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina

In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.

U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility.

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the wa

Wall Street is likely to record the fifth consecutive winning month despite volatility.

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ

Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabet